FDA Drafts Rules for Proving Generic Estradiol Works Down There
Published Date: 12/8/2025
Notice
Summary
The FDA just dropped new draft guidance for companies making estradiol vaginal inserts and tablets. This guidance helps drug makers design studies to prove their products work the same as already approved ones, speeding up approval. Industry folks should send their feedback by February 6, 2026, so the FDA can finalize the rules—saving time and money in the long run!
Analyzed Economic Effects
4 provisions identified: 3 benefits, 0 costs, 1 mixed.
Draft BE Guidance for Estradiol Generics
If you make generic estradiol vaginal products, the FDA released draft product-specific guidances that give recommendations on the design of bioequivalence (BE) studies to support abbreviated new drug applications (ANDAs) for estradiol vaginal inserts and estradiol vaginal tablets. The guidance names IMVEXXY (NDA 208564, approved May 2018) as the reference listed drug (RLD) for vaginal inserts and VAGIFEM (NDA 020908, approved March 1999) as the RLD for vaginal tablets.
Stakeholder Comment Deadline
Stakeholders, including drug makers, must submit electronic or written comments on the draft guidances by February 6, 2026 for FDA to consider them before it begins work on final versions. Comments go to docket FDA-2007-D-0369 via Regulations.gov or written/paper submission to FDA's Dockets Management Staff.
Paperwork Collections and OMB Approvals
The draft guidances contain no new collections of information but refer to previously approved FDA collections under OMB control numbers 0910-0014 (21 CFR part 312 for investigational new drugs) and 0910-0001 (21 CFR part 314 and part 320 for applications and bioequivalence requirements).
FDA Will Consider Cost Comments
As FDA develops any final guidance, it will consider comments on costs or cost savings the guidance may generate, including comments relevant to Executive Order 14192. Stakeholders may submit such comments by February 6, 2026.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2025-04978, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA is delaying a new rule about nonprescription drugs that have extra conditions for use. Originally set to start on March 21, 2025, the rule’s start date is now pushed back to May 27, 2025, to allow more time for review. This affects drug makers and consumers by giving everyone extra time to prepare for the new requirements without any immediate cost changes.
2025-01840, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA’s new rule about nonprescription drugs needing extra conditions before use was set to start on January 27, 2025, but it’s now delayed until March 21, 2025. This delay follows a presidential order to pause and review new rules before they take effect. Drug makers, sellers, and consumers should note the new start date and get ready for the updated rules soon.
2026-20730, Elite Laboratories, Inc. et al.; Withdrawal of Approval of 16 Abbreviated New Drug Applications; Correction
The FDA fixed a previous announcement about pulling approval for 16 generic drug applications. Three drugs from Navinta LLC—ribavirin solution, fosaprepitant powder, and nicardipine capsules—won't lose approval because Navinta asked to keep them active. This means those three drugs stay on the market, while the other 13 still had their approvals withdrawn as planned back in July 2026.
Previous / Next Documents
Previous: 2025-22247, Final Flood Hazard Determinations
FEMA has finalized updates to flood risk maps for several communities, changing flood zones and water levels that affect flood insurance rules. Homeowners and businesses in these areas should check the new maps by September 3, 2025, because these changes could impact insurance costs and building rules. These updates help keep communities safer and insurance programs fair.
Next: 2025-22251, Change in Bank Control Notices; Acquisitions of Shares of a Bank or Bank Holding Company
Some folks want to buy shares in banks or bank companies, and the Federal Reserve is checking their applications to make sure everything’s on the up and up. If you want to share your thoughts, you’ve got until December 23, 2025, to speak up. This process helps keep banks safe and sound while letting new owners step in smoothly.